The results indicated that oCGI Chr11:728884-729383 may regulates glioma proliferation by modulating the regulatory effect of TFs E2F7 on the target gene POLR2L. Clinical drugs were selected based on distinct oCGIs-based glioma subtypes. Here, E2F7 is linked to central nervous system cancer.